Treatments for spinal cord injury: Is there hope in neurosteroids?

Journal of Steroid Biochemistry and Molecular Biology

Volumn 109, Issue 3-5, 2008, Pages 307-313

  Compagnone, Nathalie A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bladder control; DHEA; Drug development; Methylprednisolone; Motor recovery; Neurosteroid; Sonic hedgehog; Spinal cord injury

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; 4 AMINOPYRIDINE; NEUROSTEROID; PRASTERONE; PROGESTERONE; SONIC HEDGEHOG PROTEIN;

ARTICLE; CELL PROLIFERATION; CELL TRANSPLANTATION; DEMYELINATION; DRUG EFFECT; DRUG MECHANISM; HUMAN; NERVE FIBER GROWTH; NEURAL TUBE; NEUROPROTECTION; NONHUMAN; PHYSIOTHERAPY; SPINAL CORD INJURY;

ANIMALS; CELL TRANSPLANTATION; CLINICAL TRIALS AS TOPIC; HUMANS; MYELIN SHEATH; NERVE REGENERATION; SPINAL CORD INJURIES; STEROIDS;

ERINACEIDAE;

EID: 45449121003     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2008.03.022     Document Type: Article

References (67)

1. Taoka Y., and Okajima K. Spinal cord injury in the rat. Prog. Neurobiol. 56 3 (1998) 341-358
2. Hagg T., and Oudega M. Degenerative and spontaneous regenerative processes after spinal cord injury. J. Neurotrauma 23 3-4 (2006) 264-280
3. Bracken M.B., et al. Clinical measurement, statistical analysis, and risk-benefit: controversies from trials of spinal injury. J. Trauma 48 March (3) (2000) 558-561
4. Nesathurai S. Steroids and spinal cord injury: revisiting the nascis 2 and nascis 3 trials. J. Trauma 45 6 (1998) 1088-1093
5. Molano Mdel R., et al. Complications associated with the prophylactic use of methylprednisolone during surgical stabilization after spinal cord injury. J. Neurosurg. 96 Suppl. 3 (2002) 267-272
6. Qian T., et al. High-dose methylprednisolone may do more harm for spinal cord injury. Med. Hypotheses 55 5 (2000) 452-453
7. Hurlbert R.J. Methylprednisolone for acute spinal cord injury: an inappropriate standard of care. J. Neurosurg. 93 Suppl. 1 (2000) 1-7
8. Hurlbert R.J. Strategies of medical intervention in the management of acute spinal cord injury. Spine 31 Suppl. 11 (2006) S16-S21 (discussion S36)
9. Short D.J., et al. High dose methylprednisolone in the management of acute spinal cord injury-a systematic review from a clinical perspective. Spinal Cord 38 5 (2000) 273-286
10. Dumont R.J., et al. Acute spinal cord injury, part ii: contemporary pharmacotherapy. Clin. Neuropharmacol. 24 5 (2001) 265-279
11. Hall E.D., and Springer J.E. Neuroprotection and acute spinal cord injury: a reappraisal. NeuroRx 1 1 (2004) 80-100
12. Li M., et al. Myelin-associated glycoprotein inhibits neurite/axon growth and causes growth cone collapse. J. Neurosci. Res. 46 4 (1996) 404-414
13. Fitch M.T., and Silver J. Activated macrophages and the blood-brain barrier: Inflammation after cns injury leads to increases in putative inhibitory molecules. Exp. Neurol. 148 2 (1997) 587-603
14. Fouad K., et al. Improving axonal growth and functional recovery after experimental spinal cord injury by neutralizing myelin associated inhibitors. Brain Res. Brain Res. Rev. 36 2-3 (2001) 204-212
15. Jones L.L., et al. Ng2 is a major chondroitin sulfate proteoglycan produced after spinal cord injury and is expressed by macrophages and oligodendrocyte progenitors. J. Neurosci. 22 7 (2002) 2792-2803
16. Schwab J.M., et al. The nogo receptor complex: confining molecules to molecular mechanisms. Trends Mol. Med. 12 7 (2006) 293-297
17. Tan A.M., et al. Antibodies against the ng2 proteoglycan promote the regeneration of sensory axons within the dorsal columns of the spinal cord. J. Neurosci. 26 18 (2006) 4729-4739
18. Goldshmit Y., et al. Roles of eph receptors and ephrins in the normal and damaged adult cns. Brain Res. Brain Res. Rev. 52 2 (2006) 327-345
19. Chen Z.J., et al. Inhibition of axon growth by oligodendrocyte precursor cells. Mol. Cell. Neurosci. 20 1 (2002) 125-139
20. Prinjha R.K., et al. Strategies for developing Nogo antagonists. Drug discovery today vol1 (2004) 21-27
21. Bito H., et al. A critical role for a rho-associated kinase, p160rock, in determining axon outgrowth in mammalian cns neurons. Neuron 26 2 (2000) 431-441
22. Niederost B., et al. Nogo-a and myelin-associated glycoprotein mediate neurite growth inhibition by antagonistic regulation of rhoa and rac1. J. Neurosci. 22 23 (2002) 10368-10376
23. Alabed Y.Z., et al. Neuronal responses to myelin are mediated by rho kinase. J. Neurochem. 96 6 (2006) 1616-1625
24. Schwab J.M., et al. Experimental strategies to promote spinal cord regeneration-an integrative perspective. Prog. Neurobiol. 78 2 (2006) 91-116
25. Mcdonald J.W., et al. Transplanted embryonic stem cells survive, differentiate and promote recovery in injured rat spinal cord. Nat. Med. 5 12 (1999) 1410-1412
26. Liu Y., et al. Grafts of bdnf-producing fibroblasts rescue axotomized rubrospinal neurons and prevent their atrophy. Exp. Neurol. 178 2 (2002) 150-164
27. Eaton M. Cell therapy for neuropathic pain in spinal cord injuries. Expert Opin. Biol. Ther. 4 12 (2004) 1861-1869
28. Cao Q.L., et al. Pluripotent stem cells engrafted into the normal or lesioned adult rat spinal cord are restricted to a glial lineage. Exp. Neurol. 167 1 (2001) 48-58
29. Ramon-Cueto A., et al. Long-distance axonal regeneration in the transected adult rat spinal cord is promoted by olfactory ensheathing glia transplants. J. Neurosci. 18 10 (1998) 3803-3815
30. Bartolomei J.C., and Greer C.A. Olfactory ensheathing cells: bridging the gap in spinal cord injury. Neurosurgery 47 5 (2000) 1057-1069
31. Ibrahim A., et al. Olfactory ensheathing cells: ripples of an incoming tide?. Lancet Neurol. 5 5 (2006) 453-457
32. Li Y., et al. Interaction of olfactory ensheathing cells with astrocytes may be the key to repair of tract injuries in the spinal cord: the 'pathway hypothesis'. J. Neurocytol. 34 3-5 (2005) 343-351
33. Curt A., and Dietz V. Controversial treatments for spinal-cord injuries. Lancet 365 9462 (2005) 841
34. Lima C., et al. olfactory mucosa autografts in human spinal cord injury : a pilot study. J spinal cord med. 29 3 (2006) 191-203
35. Feron F., et al. Autologous olfactory ensheathing cell transplantation in human SCI. Brain dec 128 (2005) 2951-2960
36. Hauben E., and Schwartz M. Therapeutic vaccination for spinal cord injury: helping the body to cure itself. Trends Pharmacol. Sci. 24 1 (2003) 7-12
37. Hicks A.L., et al. Long-term body-weight-supported treadmill training and subsequent follow-up in persons with chronic sci: effects on functional walking ability and measures of subjective well-being. Spinal Cord 43 5 (2005) 291-298
38. Effing T.W., et al. Body weight-supported treadmill training in chronic incomplete spinal cord injury: a pilot study evaluating functional health status and quality of life. Spinal Cord 44 5 (2006) 287-296
39. Tewari M.K., et al. Diagnosis and prognostication of adult spinal cord injury without radiographic abnormality using magnetic resonance imaging: analysis of 40 patients. Surg. Neurol. 63 3 (2005) 204-209 (discussion 209)
40. Garcia Leoni M.E., and Esclarin De Ruz A. Management of urinary tract infection in patients with spinal cord injuries. Clin. Microbiol. Infect. 9 8 (2003) 780-785
41. Krassioukov A., and Claydon V.E. The clinical problems in cardiovascular control following spinal cord injury: an overview. Prog. Brain Res. 152 (2006) 223-229
42. Steeves J., et al. Report of international clinical trials workshop on spinal cord injury February 20-21, 2004, Vancouver, Canada. Spinal Cord 42 10 (2004) 591-597
43. Anderson D.K., et al. Recommended guidelines for studies of human subjects with spinal cord injury. Spinal Cord 43 8 (2005) 453-458
44. Compagnone N.A., and Mellon S.H. Neurosteroids: biosynthesis and function of these novel neuromodulators. Front. Neuroendocrinol. 21 (2000) 1-60
45. Webb S.J., et al. The biological actions of dehydroepiandrosterone involves multiple receptors. Drug Metab. Rev. 38 1-2 (2006) 89-116
46. Marx C.E., et al. Neurosteroid modulation of embryonic neuronal survival in vitro following anoxia. Brain Res. 871 1 (2000) 104-112
47. Gubba E.M., et al. The effects of corticosterone and dehydroepiandrosterone on neurotrophic factor mrna expression in primary hippocampal and astrocyte cultures. Brain Res. Mol. Brain Res. 127 1-2 (2004) 48-59
48. Loria R.M., et al. Regulation of the immune response by dehydroepiandrosterone and its metabolites. J. Endocrinol. 150 Suppl. (1996) S209-S220
49. Mclachlan J.A., et al. Dehydroepiandrosterone modulation of lipopolysaccharide-stimulated monocyte cytotoxicity. J. Immunol. 156 1 (1996) 328-335
50. Kimonides V.G., et al. Dehydroepiandrosterone (dhea) and dhea-sulfate (dheas) protect hippocampal neurons against excitatory amino acid-induced neurotoxicity. Proc. Natl. Acad. Sci. U.S.A. 95 4 (1998) 1852-1857
51. Bastianetto S., et al. Dehydroepiandrosterone (dhea) protects hippocampal cells from oxidative stress-induced damage. Brain Res. Mol. Brain Res. 66 1-2 (1999) 35-41
52. Barger S.W., et al. Dehydroepiandrosterone inhibits microglial nitric oxide production in a stimulus-specific manner. J. Neurosci. Res. 62 4 (2000) 503-509
53. Compagnone N.A., and Mellon S.H. Dehydroepiandrosterone: a potential signalling molecule for neocortical organization during development. Proc. Natl. Acad. Sci. U.S.A. 95 April (1998) 4678-4683
54. Maclusky N.J., et al. Effects of dehydroepiandrosterone and flutamide on hippocampal ca1 spine synapse density in male and female rats: implications for the role of androgens in maintenance of hippocampal structure. Endocrinology 145 9 (2004) 4154-4161
55. Suzuki M., et al. Mitotic and neurogenic effects of dehydroepiandrosterone (dhea) on human neural stem cell cultures derived from the fetal cortex. Proc. Natl. Acad. Sci. U.S.A. 101 9 (2004) 3202-3207
56. Compagnone N.A., et al. Steroidogenic enzyme p450c17 is expressed in the embryonic central nervous system. Endocrinology 136 11 (1995) 5212-5223
57. Fiore C., et al. Treatment with the neurosteroid dehydroepiandrosterone promotes recovery of motor behavior after moderate contusive spinal cord injury in the mouse. J. Neurosci. Res. 75 3 (2004) 391-400
58. Chen J., et al. Differential expression of cell fate determinants in neurons and glial cells of adult mouse spinal cord after compression injury. Eur. J. Neurosci. 22 8 (2005) 1895-1906
59. Thomas A.J., et al. Progesterone is neuroprotective after acute experimental spinal cord trauma in rats. Spine 24 20 (1999) 2134-2138
60. Gonzalez S.L., et al. Progesterone neuroprotection in spinal cord trauma involves up-regulation of brain-derived neurotrophic factor in motoneurons. J. Steroid Biochem. Mol. Biol. 94 1-3 (2005) 143-149
61. He J., et al. Progesterone and allopregnanolone reduce inflammatory cytokines after traumatic brain injury. Exp. Neurol. 189 2 (2004) 404-412
62. Mure P.Y., et al. Bladder function after incomplete spinal cord injury in mice: quantifiable outcomes associated with bladder function and efficiency of dehydroepiandrosterone as a therapeutic adjunct. J. Neurosurg. 100 Suppl. Spine 1 (2004) 56-61
63. De Groat W.C., et al. Developmental and injury induced plasticity in the micturition reflex pathway. Behav. Brain Res. 92 2 (1998) 127-140
64. Yamada T., et al. Control of cell pattern in the neural tube: motor neuron induction by diffusible factors from notochord and floor plate. Cell 73 4 (1993) 673-686
65. Fuse N., et al. Sonic hedgehog protein signals not as a hydrolytic enzyme but as an apparent ligand for patched. Proc. Natl. Acad. Sci. U.S.A. 96 20 (1999) 10992-10999
66. Pepinsky R.B., et al. Mapping sonic hedgehog-receptor interactions by steric interference. J. Biol. Chem. 275 15 (2000) 10995-11001
67. Basso D.M., et al. A sensitive and reliable locomotor rating scale for open field testing in rats. J. Neurotrauma 12 1 (1995) 1-21